Breaking Down SG&A Expenses: Genmab A/S vs CRISPR Therapeutics AG

A Comparative Analysis of SG&A Expenses: Genmab A/S vs CRISPR Therapeutics AG

In the dynamic world of biotechnology, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Genmab A/S and CRISPR Therapeutics AG, from 2014 to 2023. Over this period, Genmab A/S has consistently outpaced CRISPR Therapeutics AG in SG&A spending, reflecting its expansive operational scale. In 2023, Genmab's SG&A expenses surged to nearly 3.3 billion, marking a staggering 3140% increase from 2014. In contrast, CRISPR Therapeutics AG's expenses peaked in 2021 at approximately 102 million, a 1900% rise from 2014, before slightly declining. This trend underscores Genmab's aggressive growth strategy and market positioning, while CRISPR's more conservative approach highlights its focus on innovation and research. Such insights are invaluable for investors and stakeholders aiming to navigate the biotech landscape.